| pubmed-article:20227876 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20227876 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:20227876 | lifeskim:mentions | umls-concept:C1120843 | lld:lifeskim |
| pubmed-article:20227876 | lifeskim:mentions | umls-concept:C0072662 | lld:lifeskim |
| pubmed-article:20227876 | lifeskim:mentions | umls-concept:C1366876 | lld:lifeskim |
| pubmed-article:20227876 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:20227876 | lifeskim:mentions | umls-concept:C2744455 | lld:lifeskim |
| pubmed-article:20227876 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:20227876 | pubmed:dateCreated | 2010-4-5 | lld:pubmed |
| pubmed-article:20227876 | pubmed:abstractText | Starting from an initial HTS screening lead, a novel series of C(5)-substituted diaryl pyrazoles were developed that showed potent inhibition of p38alpha kinase. Key to this outcome was the switch from a pyridyl to pyrimidine at the C(4)-position leading to analogs that were potent in human whole blood based cell assay as well as in a number of animal efficacy models for rheumatoid arthritis. Ultimately, we identified a clinical candidate from this substrate; SD-0006. | lld:pubmed |
| pubmed-article:20227876 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20227876 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20227876 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20227876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20227876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20227876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20227876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20227876 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20227876 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20227876 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:20227876 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:LindmarkR JRJ | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:MonahanJoseph... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:YangSyaulanS | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:FlynnDaniel... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:NaingWinW | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:MessingDean... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:BensonAlan... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:PortanovaJose... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:KimTinaT | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:DevrajRajesh... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:SelnessShaun... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:WalkerJohn... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:ShiehHueyH | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:HepperleMicha... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:KurambailRavi... | lld:pubmed |
| pubmed-article:20227876 | pubmed:author | pubmed-author:DiceTomT | lld:pubmed |
| pubmed-article:20227876 | pubmed:copyrightInfo | Copyright 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20227876 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20227876 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:20227876 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:20227876 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20227876 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20227876 | pubmed:pagination | 2634-8 | lld:pubmed |
| pubmed-article:20227876 | pubmed:meshHeading | pubmed-meshheading:20227876... | lld:pubmed |
| pubmed-article:20227876 | pubmed:meshHeading | pubmed-meshheading:20227876... | lld:pubmed |
| pubmed-article:20227876 | pubmed:meshHeading | pubmed-meshheading:20227876... | lld:pubmed |
| pubmed-article:20227876 | pubmed:meshHeading | pubmed-meshheading:20227876... | lld:pubmed |
| pubmed-article:20227876 | pubmed:meshHeading | pubmed-meshheading:20227876... | lld:pubmed |
| pubmed-article:20227876 | pubmed:meshHeading | pubmed-meshheading:20227876... | lld:pubmed |
| pubmed-article:20227876 | pubmed:meshHeading | pubmed-meshheading:20227876... | lld:pubmed |
| pubmed-article:20227876 | pubmed:meshHeading | pubmed-meshheading:20227876... | lld:pubmed |
| pubmed-article:20227876 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20227876 | pubmed:articleTitle | Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. | lld:pubmed |
| pubmed-article:20227876 | pubmed:affiliation | Pfizer Global Research and Development, St. Louis, MO 63017, USA. jkwalker24@sbcglobal.net | lld:pubmed |
| pubmed-article:20227876 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20227876 | lld:chembl |
